Human recombinant cytokines were purchased from Peprotech (Rocky Hill, NJ, USA): melanoma growth stimulating activity-α/CXCL1, used at a working concentration of 50 ng/mL; macrophage inflammatory protein 2-α/CXCL2, used at a working concentration of 100 ng/mL; and interleukin (IL)-8/CXCL8, used at a working concentration of 50 ng/mL. Antibodies were purchased from R&D Systems (Minneapolis, MN, USA): mouse anti-human granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody (clone 3209, isotype IgG1), used at a working concentration of 0.5 to 1.5 μg/mL; mouse anti-human CXCL8 antibody (clone 6217, isotype IgG1), used at a working concentration of 0.5 to 1.5 μg/mL; anti-human IL-18 antibody (clone 125-2H, isotype IgG1), used at a working concentration of 1.0 to 3.0 μg/mL; mouse anti-human IL-6 antibody (clone 1936, isotype IgG2b), used at a working concentration of 0.15 to 0.45 μg/mL; and mouse anti-human CXCL1 antibody (clone 20326, isotype IgG2b), used at a working concentration of 7.5 μg/mL. Purified mouse IgG1 (clone MOPC-21) and Mouse IgG2b (clone MPC-11; BD Pharmingen, San Diego, CA, USA) were used as negative control antibodies at the same concentrations as the specific blocking antibodies.